Evidence map›Paper›PMID 41036084›Full record

ArticleJournal of kidney cancer and VHL2025

Visfatin Promotes Renal Cell Carcinoma Progression: Evidence from Clinical Samples and Cell Line Models.

Eiji Kashiwagi, Miho Ushijima, Shohei Ueda, Yoshihiro Sugita, Yui Mizushima, Takuo Matsukawa, Rieko Kimuro, Kazumasa Jojima, Katsuyoshi Higashijima, Yujiro Nagata and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of kidney cancer and VHL, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Eiji KashiwagiDepartment of Urology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Miho UshijimaDepartment of Urology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Shohei UedaDepartment of Urology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Yoshihiro SugitaDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Yui MizushimaDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Takuo MatsukawaDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Rieko KimuroDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kazumasa JojimaDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Katsuyoshi HigashijimaDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Yujiro NagataDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Akinori MinatoDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Ikko TomisakiDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Masatoshi EtoDepartment of Urology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The kidney is enveloped by perirenal fat, which secretes various hormones and cytokines, known as adipokines. Adipokines have been demonstrated to influence the development and progression of tumors, including renal cell carcinoma (RCC). Visfatin, an adipokine secreted by the adipose tissue, has been implicated in RCC, but its precise role remains unclear. In this study, we investigated the expression of visfatin in perirenal fat from patients with RCC and its correlation with the RCC malignant phenotype, and we examined the role of visfatin in RCC cell lines in vitro. This study included adipose tissue samples from 57 Japanese patients with clear cell RCC who underwent partial or radical nephrectomy. We examined the mRNA expression level of visfatin using real-time PCR. In vitro MTT assay and western blot were performed using human RCC cell lines. The mRNA expression of visfatin in peri-tumor versus peri-normal fat was higher in Fuhrman grade ≥2 cases compared with Fuhrman grade 1 cases. Furthermore, the addition of visfatin to RCC cell lines promoted cell proliferation, which was accompanied by increased protein expression of HIF1α, p-Akt, and p-ERK. Conversely, the addition of FK866, a visfatin inhibitor, suppressed cell proliferation and reduced these proteins. Our findings suggest that visfatin from peri-tumor adipose tissue influences the malignancy of RCC and plays a role in promoting the growth of RCC. This indicates a potential mechanism by which adipose tissue contributes to the progression of RCC, providing a possible target for therapeutic intervention.

Indexed as

AdipocytokineAdipose tissuePerirenal fatRenal cell carcinomaVisfatin

Identifiers

PMID41036084
PMCPMC12481047

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.